Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-100 in MDD and PTSD
NCT05117632Phase 2Completed
- Sponsor
- Alto Neuroscience
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amdiglurax in major depressive disorder (MDD), post-traumatic stress disorder (PTSD), sponsored by Alto Neuroscience. Started Dec 2021; status: completed.
02
Drugs
amdiglurax
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05117632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117632.